Drugs / Lactobacillus
Lactobacillus
also known as
Probiotic Formula · Bifidobacterium lactis · live combined Bifidobacterium and Lactobacillus · Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules · B. lactis · Bifidobacterium animalis ssp. lactis · Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live · L. johnsonii N6.2 · +3 more
Trials 14 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02349360 Comparator | Aug 2015 → Dec 2016 | — | University of Florida | Completed | No outcome recorded |
| Phase 1/2 | NCT00746226 Comparator | Mar → Jun 2006 | seasonal allergic rhinitis | Danisco | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06253988 Comparator | Jan → Feb 2023 | periodontitis | Al-Azhar University | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04699240 Comparator | Jul 2020 → Dec 2023 | vulvovaginal candidiasis | Peking University Shenzhen Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03099408 Comparator | Jul 2017 → Dec 2020 | bacterial vaginosis | Peking University Shenzhen Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01497743 Comparator | Feb 2012 → Feb 2013 | systemic sclerosis | University of Michigan | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06467942 Comparator | Mar 2023 → Dec 2024 | human papilloma virus infection | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus | “One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days” NCT06788132 ↗6“Target isolation and culture of core beneficial bacteria (Lactobacillus and Bifidobacterium)” NCT07188909 ↗ |
| Known as | B. lactis | “Active was a strawberry yogurt-based drink supplemented with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12.” PMID 20216564 ↗ Mar 2010 |
| Known as | Bifidobacterium animalis ssp. lactis | “Active was a strawberry yogurt-based drink supplemented with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12.” PMID 20216564 ↗ Mar 2010 |
| Known as | Bifidobacterium lactis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02535962 ↗ |
| Known as | Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live | “Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live)” NCT06960369 ↗ |
| Known as | L. johnsonii N6.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02349360 ↗ |
| Known as | Lactobacillus johnsonii N6.2 | “Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults.” PMID 28659913 ↗ Jun 2017 |
| Known as | live combined Bifidobacterium and Lactobacillus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03556631 ↗ |
| Known as | Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871464 ↗ |
| Known as | live combined Bifidobacteriun, Lactobacillus and Enterococcus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05901779 ↗ |
| Known as | Live Probiotic tablet | “Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live)” NCT06960369 ↗ |
| Known as | Probiotic Formula | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03021161 ↗ |
| Action | Activate | “oral administration of lactobacillus can boost NK-T cell activity in children with HIV without side effects” NCT00011141 ↗ |
| Modality | Other / unclassified | “The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria...” NCT02349360 ↗ |
| Route | Oral | “Oral lactobacillus administration” NCT00011141 ↗ |